As Gottlieb leaves, what’s next for FDA?

As Norman “Ned” E. Sharpless, MD, prepares to become acting FDA commissioner in a few days, experts are divided in how he should address the explosion of e-cigarette use among minors and the devastating opioid epidemic whose tide has not turned.
He also faces the challenges of reinvigorating antibiotic development and lowering drug prices.
These areas were some of his predecessor, Scott Gottlieb, MD’s, main focus.
Though Sharpless has indicated elsewhere he would follow Gottlieb’s lead, it’s unclear if Sharpless will be the permanent nominee. Some have also

Source link

Related posts

FDA: Modeling, simulation offer opportunity to advance public health


Screening for Lynch syndrome less efficient after age 70 to 75 years


No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-related Mortality in Patients with Cirrhosis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy